Raj S. Kasthuri

Raj S. Kasthuri

Auto-generated profile, based on publicly available information

Raj S. Kasthuri

Department of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2020 in Annals of Internal Medicine
Verified
Journal Article
Open access
MFMd Marie E. Faughnan
Md Marie E. Faughnan
JMJohannes J. Mager
Johannes J. Mager
SHSteven W. Hetts
Steven W. Hetts
VPValerie A. Palda
Valerie A. Palda
KLKelly Lang-Robertson
Kelly Lang-Robertson
RZRoberto Zarrabeitia
Roberto Zarrabeitia
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease affecting multiple organ systems. The Second International HHT Guidelines provide evidence-informed consensus guidelines... Description: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of vascular malformations (...

11 February 2021 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
SGSteven Grover
Steven Grover
YHYohei M. Hisada
Yohei M. Hisada
RKRaj S. Kasthuri
Raj S. Kasthuri
BRBRANDI REEVES
BRANDI REEVES
NMNigel Mackman
Nigel Mackman
Patients with cancer have an increased risk of both arterial and venous thrombotic events compared with the general population. Both the site and stage of cancer are known to contribute to the increased risk of thrombotic events. In addition, several treatment-related factors enhance the risk of thrombosis, including hospitalization, surgery, central venous catheters, radiation, and anticancer agents. Chemotherapy serves as a mainstay treatment for a broad range of malignancies. Chemotherapeutic agents typically exert antineoplastic effects through either direct cytotoxicity or inhibition of cellular processes necessary for the proliferation of malignant cells. Unfortunately, in addition to targeting malignant cells, chemotherapeutic agents are also cytotoxic to nonmalignant cells. Chemotherapeutic agents have been associated with an increased risk of arterial and venous thrombosis. More recently, targeted agents have been developed that offer improved selectivity towards malignant cells. However, some of these agents are also associated with an increased risk of both arterial and venous thrombosis. Here, we review the association between specific anticancer agents and thrombotic events in patients with cancer. Despite an established association in most cases, the mechanism by which these agents increase thrombosis is poorly understood. Anticancer agents may damage the endothelium, decrease anticoagulants or increase procoagulants leading to activation of coagulation, or activate platelets. An improved understanding of the mechanisms that drive the increased risk of thrombotic events associated with anticancer agents will enable treatment strategies that mitigate this risk.

31 May 2012 in Blood
Verified
Journal Article
Closed access
PDF file
RKRaj S. Kasthuri
Raj S. Kasthuri
SGSam L. Glover
Sam L. Glover
WJWilliam Jonas
William Jonas
TMTroy McEachron
Troy McEachron
RPRafal Pawlinski
Rafal Pawlinski
NMNigel Mackman
Nigel Mackman
Heparin-induced thrombocytopenia (HIT) is a potentially devastating form of drug-induced thrombocytopenia that occurs in patients receiving heparin for prevention or treatment of thrombosis. Patients with HIT develop autoantibodies to the platelet factor 4 (PF4)/heparin complex, which is termed the HIT Ab complex. Despite a decrease in the platelet count, the most feared complication of HIT is thrombosis. The mechanism of thrombosis in HIT remains poorly understood. We investigated the effects of the HIT Ab complex on tissue factor (TF) expression and release of TF-positive microparticles in peripheral blood mononuclear cells and monocytes. To model these effects ex vivo, we used a murine mAb specific for the PF4/heparin complex (KKO), as well as plasma from patients with HIT. We found that the HIT Ab complex induced TF expression in monocytes and the release of TF-positive microparticles. Further, we found that induction of TF is mediated via engagement of the FcγRI receptor and activation of the MEK1-ERK1/2 signaling pathway. Our data suggest that monocyte TF may contribute to the development of thrombosis in patients with HIT.

9 January 2025 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
RHRuben Hermann
Ruben Hermann
CSClaire L. Shovlin
Claire L. Shovlin
RKRaj S. Kasthuri
Raj S. Kasthuri
MSMarcelo Serra
Marcelo Serra
OEOmer F. Eker
Omer F. Eker
SDSophie Dupuis-Girod
Sophie Dupuis-Girod

22 June 2017 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
RKRaj S. Kasthuri
Raj S. Kasthuri
MMMegan Montifar
Megan Montifar
JNJeffrey Nelson
Jeffrey Nelson
HKHelen Kim
Helen Kim
MLMichael T. Lawton
Michael T. Lawton
TGthe Brain Vascular Malformation Consortium HHT Investigator Group
the Brain Vascular Malformation Consortium HHT Investigator Group
Click on the article title to read more.

22 September 2022 in Blood
Verified
Journal Article
Open access
PDF file
SCShruti Chaturvedi
Shruti Chaturvedi
AAAna G. Antun
Ana G. Antun
AFAndrew M. Farland
Andrew M. Farland
RWRyan Woods
Ryan Woods
AMAra D Metjian
Ara D Metjian
FCfor the United States Thrombotic Microangiopathies Consortium
for the United States Thrombotic Microangiopathies Consortium
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, but racial disparities in iTTP outcome and response to therapy have not been studied. Using the United States Thrombotic Microangiopathies Consortium iTTP Registry, we evaluated the impact of race on mortality and relapse-free survival (RFS) in confirmed iTTP in the United States from 1995 to 2020. We separately examined the impact of rituximab therapy and presentation with newly diagnosed (de novo) or relapsed iTTP on RFS by race. A total of 645 participants with 1308 iTTP episodes were available for analysis. Acute iTTP mortality did not differ by race. When all episodes of iTTP were included, Black race was associated with shorter RFS (hazard ratio [HR], 1.60; 95% CI, 1.16-2.21); the addition of rituximab to corticosteroids improved RFS in White (HR, 0.37; 95% CI, 0.18-0.73) but not Black patients (HR, 0.96; 95% CI, 0.71-1.31). In de novo iTTP, rituximab delayed relapse, but Black patients had shorter RFS than White patients, regardless of treatment. In relapsed iTTP, rituximab significantly improved RFS in White but not Black patients. Race affects overall relapse risk and response to rituximab in iTTP. Black patients may require closer monitoring, earlier retreatment, and alternative immunosuppression after rituximab treatment. How race, racism, and social determinants of health contribute to the disparity in relapse risk in iTTP deserves further study.